Compare AstraZeneca plc (AZN) vs iShares Gold Trust (IAU) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

IAU, the iShares Gold Trust ETF, is trading at $75.25, down 2.6% with a bearish technical outlook. The ETF faces pressure from rising Treasury yields and Federal Reserve policy uncertainty, though recent weaker CPI data provided temporary support. Gold remains a key asset amid geopolitical tensions and central bank accumulation, with the fund offering low-cost exposure to physical gold.

The outlook for IAU is mixed, balancing strong long-term fundamentals against near-term headwinds. Gold's role as a hedge and central bank demand provide support, but Fed policy and dollar strength pose risks. The ETF's structure offers efficient gold access, but price volatility requires careful position sizing.